Seigneurin J M, Lavoue M F, Genoulaz O, Bornkamm G W, Lenoir G M
Int J Cancer. 1987 Sep 15;40(3):349-53. doi: 10.1002/ijc.2910400311.
Specific antibody responses against the 2 major subcomponents of EBNA, EBNA1 and EBNA2 were evaluated, in order to study whether this serological study was beneficial compared to classical EBV serology. During this investigation, 491 sera, obtained from blood donors and patients with Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), infectious mononucleosis (IM), Hodgkin's disease, renal transplantation, rheumatoid arthritis and Human Immunodeficiency Virus (HIV) infection, were tested. While the anti-EBNA1 response followed the classical anti-EBNA/Raji response (99% of anti-EBNA/Raji-positive sera also recognize EBNA1), the anti-EBNA2 response was much less frequent and did not correlate with either anti-EBNA/Raji or anti-EA antibodies. In a control population, 8% of individuals had antiEBNA2 antibodies at titers greater than or equal to 10. The percentage was 45% in NPC and 38% in EBV-associated BL; thus, although not detected in all patients with EBV-associated tumors, anti-EBNA2 serology might be a useful marker in BL and NPC. No antibody was detected in the early course of IM, but in rheumatoid arthritis and in HIV-infected patients, the percentage of positive individuals reached 54 and 68, respectively. Seroconversion to EBNA2 was noted in a few cases, including renal transplant recipients, AIDS patients, and complicated IM. This suggests that in these situations, EBNA 2 serology might represent a useful marker related to modulation of the immune status or EBV reactivation.
为了研究这项血清学研究与传统EBV血清学相比是否有益，我们评估了针对EBNA的2个主要亚成分EBNA1和EBNA2的特异性抗体反应。在这项调查中，检测了从献血者以及患有伯基特淋巴瘤（BL）、鼻咽癌（NPC）、传染性单核细胞增多症（IM）、霍奇金病、肾移植、类风湿性关节炎和人类免疫缺陷病毒（HIV）感染的患者中获得的491份血清。虽然抗EBNA1反应遵循传统的抗EBNA/Raji反应（99%的抗EBNA/Raji阳性血清也识别EBNA1），但抗EBNA2反应的频率要低得多，并且与抗EBNA/Raji或抗EA抗体均无相关性。在对照人群中，8%的个体抗EBNA2抗体滴度大于或等于10。在NPC中这一比例为45%，在EBV相关的BL中为38%；因此，尽管并非在所有EBV相关肿瘤患者中都能检测到，但抗EBNA2血清学可能是BL和NPC中的一个有用标志物。在IM的早期病程中未检测到抗体，但在类风湿性关节炎和HIV感染患者中，阳性个体的比例分别达到54%和68%。在少数情况下观察到向EBNA2的血清学转换，包括肾移植受者、艾滋病患者和复杂的IM患者。这表明在这些情况下，EBNA 2血清学可能代表与免疫状态调节或EBV重新激活相关的一个有用标志物。
